Ventana Genetics Inc. is taking a few shortcuts to drug target identification. The company's technology essentially skips the steps in genomics of identifying a gene and genes in its related pathway and elucidating their functions before determining their relevance to a disorder.

Instead, Ventana starts by identifying proteins in a cell relevant to the disease of interest and whose activity can be modulated by an outside entity, a method that the company believes will speed target identification compared to genomics methods.